Sustained release, comfort formulation for glaucoma therapy
February 5, 2008. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3867519 Structured bioerodible drug delivery device Polystyrene sulfonate containing opthalmic solutions Method of treatment for glaucoma Drug-dispensing device and method Sustained release ophthalmic drug dosage Sustained release ophthalmic drug dosage Microcapsules and method of preparing same Ophthalmic compositions and their use for treating elevated intraocular pressure and glaucoma Patent #: 4521414 InventorsApplicationNo. 154514 filed on 02/05/1988US Classes:424/78.04, Ophthalmic preparation424/78.1, Ion exchange resin424/501, Contains solid synthetic resin514/913GlaucomaExaminersPrimary: Rose, Shep K.Assistant: Fay, Zohreh Attorney, Agent or FirmInternational ClassA61K 031/78AbstractDisclosed are nonstinging, sustained release ophthalmic formulations to control intraocular pressure in antiglaucoma therapy comprising a basic active, a cation exchange resin, and, inter alia, an acidic, mucomimetic polymer. Also disclosed are methods of treatment comprising administering such formulations topically to the eye when indicated for control and lowering of intraocular pressure.Other References
Field of SearchGlaucoma | |
